A key challenge for systems neuroscience is the question of how to understand the complex network organization of the brain on the basis of neuroimaging data. Similar challenges exist in other ...specialist areas of systems biology because complex networks emerging from the interactions between multiple non-trivially interacting agents are found quite ubiquitously in nature, from protein interactomes to ecosystems. We suggest that one way forward for analysis of brain networks will be to quantify aspects of their organization which are likely to be generic properties of a broader class of biological systems. In this introductory review article we will highlight four important aspects of complex systems in general: fractality or scale-invariance; criticality; small-world and related topological attributes; and modularity. For each concept we will provide an accessible introduction, an illustrative data-based example of how it can be used to investigate aspects of brain organization in neuroimaging experiments, and a brief review of how this concept has been applied and developed in other fields of biomedical and physical science. The aim is to provide a didactic, focussed and user-friendly introduction to the concepts of complexity science for neuroscientists and neuroimagers.
£sup£18¥sup¥F-FDG PET is an important tool for the presurgical assessment of children with drug-resistant epilepsy. Standard assessment is performed visually and is often subjective and highly ...user-dependent. Voxelwise statistics can be used to remove user-dependent biases by automatically identifying areas of significant hypo- or hypermetabolism associated with the epileptogenic area. In the clinical setting, this analysis is performed using commercially available software. These software packages suffer from two main limitations when applied to pediatric PET data: pediatric scans are spatially normalized to an adult standard template, and statistical comparisons use an adult control dataset. The aim of this work was to provide a reliable observer-independent pipeline for the analysis of pediatric £sup£18¥sup¥F-FDG PET scans, as part of presurgical planning in epilepsy. Methods: A pseudocontrol dataset (19 subjects 6–9 y old, and 93 subjects 10–20 y old) was used to create two age-specific £sup£18¥sup¥F-FDG PET pediatric templates in standard pediatric space. The £sup£18¥sup¥F-FDG PET scans of 46 epilepsy patients (16 patients 6–9 y old, and 30 patients 10–17 y old) were retrospectively collated and analyzed using voxelwise statistics. This procedure was implemented with the standard pipeline available in the commercial software Scenium and an in-house Statistical Parametric Mapping, version 8 (SPM8), pipeline (including age-specific pediatric templates and reference database). A κ-test was used to assess the level of agreement between the findings of voxelwise analyses and the clinical diagnosis of each patient. The SPM8 pipeline was further validated using postsurgical seizure-free patients. Results: Improved agreement with the clinical diagnosis was reported using SPM8, in terms of focus localization, especially for the younger patient group: κ = 0.489 for Scenium versus 0.826 for SPM. The proposed pipeline also showed a sensitivity of about 70% in both age ranges for the localization of hypometabolic areas on pediatric £sup£18¥sup¥F-FDG PET scans in postsurgical seizure-free patients. Conclusion: We showed that by creating age-specific templates and using pediatric control databases, our pipeline provides an accurate and sensitive semiquantitative method for assessing the £sup£18¥sup¥F-FDG PET scans of patients under 18 y old.
F-FDG PET is an important tool for the presurgical assessment of children with drug-resistant epilepsy. Standard assessment is performed visually and is often subjective and highly user-dependent. ...Voxelwise statistics can be used to remove user-dependent biases by automatically identifying areas of significant hypo- or hypermetabolism associated with the epileptogenic area. In the clinical setting, this analysis is performed using commercially available software. These software packages suffer from two main limitations when applied to pediatric PET data: pediatric scans are spatially normalized to an adult standard template, and statistical comparisons use an adult control dataset. The aim of this work was to provide a reliable observer-independent pipeline for the analysis of pediatric
F-FDG PET scans, as part of presurgical planning in epilepsy.
A pseudocontrol dataset (19 subjects 6-9 y old, and 93 subjects 10-20 y old) was used to create two age-specific
F-FDG PET pediatric templates in standard pediatric space. The
F-FDG PET scans of 46 epilepsy patients (16 patients 6-9 y old, and 30 patients 10-17 y old) were retrospectively collated and analyzed using voxelwise statistics. This procedure was implemented with the standard pipeline available in the commercial software Scenium and an in-house Statistical Parametric Mapping, version 8 (SPM8), pipeline (including age-specific pediatric templates and reference database). A κ-test was used to assess the level of agreement between the findings of voxelwise analyses and the clinical diagnosis of each patient. The SPM8 pipeline was further validated using postsurgical seizure-free patients.
Improved agreement with the clinical diagnosis was reported using SPM8, in terms of focus localization, especially for the younger patient group: κ = 0.489 for Scenium versus 0.826 for SPM. The proposed pipeline also showed a sensitivity of about 70% in both age ranges for the localization of hypometabolic areas on pediatric
F-FDG PET scans in postsurgical seizure-free patients.
We showed that by creating age-specific templates and using pediatric control databases, our pipeline provides an accurate and sensitive semiquantitative method for assessing the
F-FDG PET scans of patients under 18 y old.
18F-FDG PET is an important tool for the presurgical assessment of children with drug-resistant epilepsy. Standard assessment is performed visually and is often subjective and highly user-dependent. ...Voxelwise statistics can be used to remove user-dependent biases by automatically identifying areas of significant hypo- or hypermetabolism associated with the epileptogenic area. In the clinical setting, this analysis is performed using commercially available software. These software packages suffer from two main limitations when applied to pediatric PET data: pediatric scans are spatially normalized to an adult standard template, and statistical comparisons use an adult control dataset. The aim of this work was to provide a reliable observer-independent pipeline for the analysis of pediatric 18F-FDG PET scans, as part of presurgical planning in epilepsy. Methods: A pseudocontrol dataset (19 subjects 6-9 y old, and 93 subjects 10-20 y old) was used to create two age-specific 18F-FDG PET pediatric templates in standard pediatric space. The 18F-FDG PET scans of 46 epilepsy patients (16 patients 6-9 y old, and 30 patients 10-17 y old) were retrospectively collated and analyzed using voxelwise statistics. This procedure was implemented with the standard pipeline available in the commercial software Scenium and an in-house Statistical Parametric Mapping, version 8 (SPM8), pipeline (including age-specific pediatric templates and reference database). A κ-test was used to assess the level of agreement between the findings of voxelwise analyses and the clinical diagnosis of each patient. The SPM8 pipeline was further validated using postsurgical seizure-free patients. Results: Improved agreement with the clinical diagnosis was reported using SPM8, in terms of focus localization, especially for the younger patient group: κ = 0.489 for Scenium versus 0.826 for SPM. The proposed pipeline also showed a sensitivity of about 70% in both age ranges for the localization of hypometabolic areas on pediatric 18F-FDG PET scans in postsurgical seizure-free patients. Conclusion: We showed that by creating age-specific templates and using pediatric control databases, our pipeline provides an accurate and sensitive semiquantitative method for assessing the 18F-FDG PET scans of patients under 18 y old.
Abstract
OBJECTIVES
Evaluation of post-treatment glioma burden remains a significant challenge in children, teenagers and young adults (TYA). The aim of this study was to evaluate the utility of ...ChoPET/MRI for evaluation of suspected disease progression in childhood and TYA gliomas.
METHODS
27 patients (mean age 14 years, range 6–21 years) with suspected glioma disease progression were evaluated with ChoPET/MRI (n=59). Relative cerebral blood volume (rCBV), apparent diffusion coefficient (ADC) and maximum standardised uptake values (SUVmax) in enhancing (enh) and non-enhancing (ne) tumour and normal-appearing white matter (wm) were calculated (rCBVenh, rCBVne, rCBVwm, ADCenh, ADCne, ADCwm, SUVenh, SUVne, SUVwm). 2 blinded radiologists scored tumour probability (1 = unlikely; 5 = definitely). Sensitivity and specificity calculated with gold standard histopathology or clinical follow-up.
RESULTS
Accuracy for the detection of residual/recurrent tumour on conventional MRI was 96.3% (91.7% ≤14 years, 100% ≥15 years) and ChoPET was 73.1% (66.7% ≤14 years, 80.0% ≥15 years). Lack of agreement was observed in 9/27 patients, with ChoPET superior to MRI in 1 case of a posterior fossa tumour. Tumour component analysis demonstrated significantly higher SUVenh and SUVne than SUVwm (SUVenh: p<0.001; SUVne: p=0.004, equivalent to results were observed for ADV and rCBV (ADCenh, ADCne: p<0.001 vs ADCwm; rCBVenh, rCBVne: p<0.001 vs rCBVwm).
CONCLUSIONS
MRI is more sensitive than ChoPET in the evaluation of suspected disease progression in TYA gliomas. However, quanititative ChoPET is able to detect enhancing and non-enhancing tumour and may be helpful in evaluating posterior fossa disease where MRI is equivocal.
•Prostate ADC repeatability has significant differences for varying b-value groups.•ADC from b0b1500 provides the least variability in prostate.•wSD for normal PZ, TZ and prostate lesions do not ...increase with increasing ADC.•ADC repeatability increases with larger ROI size in prostate.
VERDICT (Vascular, Extracellular, Restricted Diffusion for Cytometry in Tumours) MRI is a multi b-value, variable diffusion time DWI sequence that allows generation of ADC maps from different b-value and diffusion time combinations. The aim was to assess precision of prostate ADC measurements from varying b-value combinations using VERDICT and determine which protocol provides the most repeatable ADC.
Forty-one men (median age: 67.7 years) from a prior prospective VERDICT study (April 2016–October 2017) were analysed retrospectively. Men who were suspected of prostate cancer and scanned twice using VERDICT were included. ADC maps were formed using 5b-value combinations and the within-subject standard deviations (wSD) were calculated per ADC map. Three anatomical locations were analysed per subject: normal TZ (transition zone), normal PZ (peripheral zone), and index lesions. Repeated measures ANOVAs showed which b-value range had the lowest wSD, Spearman correlation and generalized linear model regression analysis determined whether wSD was related to ADC magnitude and ROI size.
The mean lesion ADC for b0b1500 had the lowest wSD in most zones (0.18–0.58x10-4 mm2/s). The wSD was unaffected by ADC magnitude (Lesion: p = 0.064, TZ: p = 0.368, PZ: p = 0.072) and lesion Likert score (p = 0.95). wSD showed a decrease with ROI size pooled over zones (p = 0.019, adjusted regression coefficient = -1.6x10-3, larger ROIs for TZ versus PZ versus lesions). ADC maps formed with a maximum b-value of 500 s/mm2 had the largest wSDs (1.90–10.24x10-4 mm2/s).
ADC maps generated from b0b1500 have better repeatability in normal TZ, normal PZ, and index lesions.
Currently teachers don't receive the training or induction they need to make their school an LGBT+ inclusive environment. This can be seen by the fact that half of schools do not teach anything ...regarding LGBT+, and only 3% include LGBT+ content in two or more subjects. This book will help transform your school into a safe and inclusive place for all students. Written with Educate & Celebrate!, an Ofsted and DFE recognised 'Best Practice Award Programme', this book gives teachers, governors and other staff the knowledge, strategies and confidence they need to implement a curriculum that is inclusive for all. Covering the changes to law, including the Equality Act 2010 which requires actively promoting acceptance, what language to use, case studies and much more, it is a must have guide for all schools.
Increasing age is the biggest risk factor for dementia, of which Alzheimer's disease is the commonest cause. The pathological changes underpinning Alzheimer's disease are thought to develop at least ...a decade prior to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging allow key pathological processes underpinning cognitive impairment - including β-amyloid depostion, vascular disease, network breakdown and atrophy - to be assessed repeatedly and non-invasively. This enables potential determinants of dementia to be delineated earlier, and therefore opens a pre-symptomatic window where intervention may prevent the onset of cognitive symptoms.
This paper outlines the clinical, cognitive and imaging protocol of "Insight 46", a neuroscience sub-study of the MRC National Survey of Health and Development. This is one of the oldest British birth cohort studies and has followed 5362 individuals since their birth in England, Scotland and Wales during one week in March 1946. These individuals have been tracked in 24 waves of data collection incorporating a wide range of health and functional measures, including repeat measures of cognitive function. Now aged 71 years, a small fraction have overt dementia, but estimates suggest that ~1/3 of individuals in this age group may be in the preclinical stages of Alzheimer's disease. Insight 46 is recruiting 500 study members selected at random from those who attended a clinical visit at 60-64 years and on whom relevant lifecourse data are available. We describe the sub-study design and protocol which involves a prospective two time-point (0, 24 month) data collection covering clinical, neuropsychological, β-amyloid positron emission tomography and magnetic resonance imaging, biomarker and genetic information. Data collection started in 2015 (age 69) and aims to be completed in 2019 (age 73).
Through the integration of data on the socioeconomic environment and on physical, psychological and cognitive function from 0 to 69 years, coupled with genetics, structural and molecular imaging, and intensive cognitive and neurological phenotyping, Insight 46 aims to identify lifetime factors which influence brain health and cognitive ageing, with particular focus on Alzheimer's disease and cerebrovascular disease. This will provide an evidence base for the rational design of disease-modifying trials.
Celotno besedilo
Dostopno za:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
Studies show evidence of longitudinal brain volume decreases in schizophrenia. We studied brain volume changes and their relation to symptom severity, level of function, cognition, and antipsychotic ...medication in participants with schizophrenia and control participants from a general population based birth cohort sample in a relatively long follow-up period of almost a decade. All members of the Northern Finland Birth Cohort 1966 with any psychotic disorder and a random sample not having psychosis were invited for a MRI brain scan, and clinical and cognitive assessment during 1999-2001 at the age of 33-35 years. A follow-up was conducted 9 years later during 2008-2010. Brain scans at both time points were obtained from 33 participants with schizophrenia and 71 control participants. Regression models were used to examine whether brain volume changes predicted clinical and cognitive changes over time, and whether antipsychotic medication predicted brain volume changes. The mean annual whole brain volume reduction was 0.69% in schizophrenia, and 0.49% in controls (p = 0.003, adjusted for gender, educational level, alcohol use and weight gain). The brain volume reduction in schizophrenia patients was found especially in the temporal lobe and periventricular area. Symptom severity, functioning level, and decline in cognition were not associated with brain volume reduction in schizophrenia. The amount of antipsychotic medication (dose years of equivalent to 100 mg daily chlorpromazine) over the follow-up period predicted brain volume loss (p = 0.003 adjusted for symptom level, alcohol use and weight gain). In this population based sample, brain volume reduction continues in schizophrenia patients after the onset of illness, and antipsychotic medications may contribute to these reductions.
Celotno besedilo
Dostopno za:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
PDF
